Barclays analyst Matt Miksic raised the firm’s price target on Globus Medical (GMED) to $114 from $106 and keeps an Overweight rating on the shares. The firm upped estimates following the company’s “impressive” Q3 beat.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $79 from $66 at Wells Fargo
- Globus Medical price target raised to $90 from $80 at Piper Sandler
- Globus Medical upgraded to Buy from Neutral at BofA
- Cautious Optimism: Hold Rating for Globus Medical Amid Strong Performance and Revenue Concerns
- Globus Medical upgraded to Buy from Hold at Truist